Diabetes combo trial pulled before it even started

NCT ID NCT07172867

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study was designed to test whether adding ofirnoflast to semaglutide helps obese people with type 2 diabetes control blood sugar and lose more weight than semaglutide alone. It was a Phase 2 trial planned for about 200 participants, but it was withdrawn before anyone enrolled. No results are available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

ofirnoflast (HT-6184) and semaglutide

What this could lead to

If it works, this combination could improve blood sugar control and weight loss more than semaglutide alone for people with type 2 diabetes and obesity.

What could go wrong

The trial was withdrawn before enrolling any participants, so no data exists. It is unclear if the combination would be safe or effective.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Cleveland Clinic Abu Dhabi

    Abu Dhabi, Abu Dhabi Emirate, United Arab Emirates